» Articles » PMID: 36959936

A Plant-produced SARS-CoV-2 Spike Protein Elicits Heterologous Immunity in Hamsters

Abstract

Molecular farming of vaccines has been heralded as a cheap, safe and scalable production platform. In reality, however, differences in the plant biosynthetic machinery, compared to mammalian cells, can complicate the production of viral glycoproteins. Remodelling the secretory pathway presents an opportunity to support key post-translational modifications, and to tailor aspects of glycosylation and glycosylation-directed folding. In this study, we applied an integrated host and glyco-engineering approach, NXS/T Generation™, to produce a SARS-CoV-2 prefusion spike trimer in as a model antigen from an emerging virus. The size exclusion-purified protein exhibited a characteristic prefusion structure when viewed by transmission electron microscopy, and this was indistinguishable from the equivalent mammalian cell-produced antigen. The plant-produced protein was decorated with under-processed oligomannose N-glycans and exhibited a site occupancy that was comparable to the equivalent protein produced in mammalian cell culture. Complex-type glycans were almost entirely absent from the plant-derived material, which contrasted against the predominantly mature, complex glycans that were observed on the mammalian cell culture-derived protein. The plant-derived antigen elicited neutralizing antibodies against both the matched Wuhan and heterologous Delta SARS-CoV-2 variants in immunized hamsters, although titres were lower than those induced by the comparator mammalian antigen. Animals vaccinated with the plant-derived antigen exhibited reduced viral loads following challenge, as well as significant protection from SARS-CoV-2 disease as evidenced by reduced lung pathology, lower viral loads and protection from weight loss. Nonetheless, animals immunized with the mammalian cell-culture-derived protein were better protected in this challenge model suggesting that more faithfully reproducing the native glycoprotein structure and associated glycosylation of the antigen may be desirable.

Citing Articles

Exploring recent progress of molecular farming for therapeutic and recombinant molecules in plant systems.

Bharathi J, Suresh P, Prakash M, Muneer S Heliyon. 2024; 10(18):e37634.

PMID: 39309966 PMC: 11416299. DOI: 10.1016/j.heliyon.2024.e37634.


Tomato-made edible COVID-19 vaccine TOMAVAC induces neutralizing IgGs in the blood sera of mice and humans.

Buriev Z, Shermatov S, Usmanov D, Mirzakhmedov M, Ubaydullaeva K, Kamburova V Front Nutr. 2024; 10:1275307.

PMID: 38260078 PMC: 10800535. DOI: 10.3389/fnut.2023.1275307.


Recent advances in expression and purification strategies for plant made vaccines.

Venkataraman S, Khan I, Habibi P, Le M, Lippert R, Hefferon K Front Plant Sci. 2023; 14:1273958.

PMID: 38078091 PMC: 10701439. DOI: 10.3389/fpls.2023.1273958.


Impact of mutations on the plant-based production of recombinant SARS-CoV-2 RBDs.

Ruocco V, Vavra U, Konig-Beihammer J, Bolanos Martinez O, Kallolimath S, Maresch D Front Plant Sci. 2023; 14:1275228.

PMID: 37868317 PMC: 10588190. DOI: 10.3389/fpls.2023.1275228.


A genome-edited N. benthamiana line for industrial-scale production of recombinant glycoproteins with targeted N-glycosylation.

Kogelmann B, Melnik S, Bogner M, Kallolimath S, Stoger E, Sun L Biotechnol J. 2023; 19(1):e2300323.

PMID: 37804142 PMC: 11475529. DOI: 10.1002/biot.202300323.


References
1.
Margolin E, Chapman R, Meyers A, van Diepen M, Ximba P, Hermanus T . Production and Immunogenicity of Soluble Plant-Produced HIV-1 Subtype C Envelope gp140 Immunogens. Front Plant Sci. 2019; 10:1378. PMC: 6831737. DOI: 10.3389/fpls.2019.01378. View

2.
Shin Y, Castilho A, Dicker M, Sadio F, Vavra U, Grunwald-Gruber C . Reduced paucimannosidic N-glycan formation by suppression of a specific β-hexosaminidase from Nicotiana benthamiana. Plant Biotechnol J. 2016; 15(2):197-206. PMC: 5259580. DOI: 10.1111/pbi.12602. View

3.
Hsieh C, Goldsmith J, Schaub J, DiVenere A, Kuo H, Javanmardi K . Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science. 2020; 369(6510):1501-1505. PMC: 7402631. DOI: 10.1126/science.abd0826. View

4.
Rogers T, Zhao F, Huang D, Beutler N, Burns A, He W . Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science. 2020; 369(6506):956-963. PMC: 7299280. DOI: 10.1126/science.abc7520. View

5.
Ward B, Landry N, Trepanier S, Mercier G, Dargis M, Couture M . Human antibody response to N-glycans present on plant-made influenza virus-like particle (VLP) vaccines. Vaccine. 2014; 32(46):6098-106. DOI: 10.1016/j.vaccine.2014.08.079. View